Login to Your Account



Clinic Roundup


Tuesday, November 19, 2013
• Esperion Therapeutics Inc., of Plymouth, Mich., reported results from a Phase III trial of ETC-1002 for patients with hypercholesterolemia and a history of statin intolerance showing that the drug lowered LDL-C compared to placebo by an average of 32 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription